Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer.
Currently, IgG is the only class of antibodies employed for cancer therapy. However, harnessing the unique biological properties of a different class ( e.g., IgE) could engender potent effector cell activation, and unleash previously untapped immune mechanisms against cancer. IgE antibodies are best known for pathogenic roles in allergic diseases and for protective effector functions against parasitic infestation, often mediated by IgE Fc receptor-expressing macrophages. Notably, IgE possess a very high affinity for cognate Fc receptors expressed by tumor-associated macrophages (TAMs). This paper reviews pre-clinical studies, which indicate control of cancer growth by tumor antigen-specific IgE that recruit and re-educate TAMs towards activated profiles. The clinical development harnessing the antitumor potential of recombinant IgE antibodies in cancer patients is also discussed.
['Pellizzari|Giulia|G|', 'Bax|Heather J|HJ|', 'Josephs|Debra H|DH|', 'Gotovina|Jelena|J|', 'Jensen-Jarolim|Erika|E|', 'Spicer|James F|JF|', 'Karagiannis|Sophia N|SN|']
D000818:Animals D000951:Antigens, Neoplasm D006801:Humans D007073:Immunoglobulin E D008264:Macrophages D009369:Neoplasms D011961:Receptors, Fc
IgE macrophages cancer tumor-associated macrophage AllergoOncology FcεRI cancer immunotherapy monocytes